On this page
CTLA-4 haploinsufficiency
This condition leads to immune dysregulation, with affected individuals experiencing autoimmune complications, recurrent infections, and abnormal lymphocyte accumulation. Symptoms typically begin in childhood or adolescence, though onset and severity vary considerably between individuals.
Overview
CTLA-4 haploinsufficiency arises when a person carries one pathogenic variant in the CTLA4 gene, reducing production of the CTLA-4 regulatory protein by approximately half. This protein acts as a crucial brake on immune cell activation, preventing excessive immune responses. When CTLA-4 levels are insufficient, T-lymphocytes become overactive, attacking the body's own tissues whilst simultaneously failing to respond appropriately to infections. The condition was first characterised in 2014 and remains relatively newly recognised in clinical genetics.
The disorder primarily affects the immune system, though consequences extend to multiple organ systems depending on which tissues become targets of autoimmune attack. Most individuals develop symptoms before age 20, though some remain mildly affected or undiagnosed until adulthood. The clinical picture varies substantially even within families carrying identical CTLA4 variants, suggesting additional genetic or environmental factors influence disease expression.
Symptoms & clinical features
Affected individuals typically present with recurrent respiratory tract infections alongside autoimmune manifestations. Common features include chronic diarrhoea due to autoimmune enteropathy, low blood counts affecting platelets and red cells, and enlarged lymph nodes or spleen. Some people develop autoimmune thyroid disease, type 1 diabetes, or inflammatory arthritis. Skin manifestations may include eczema, psoriasis, or other inflammatory rashes.
Neurological complications occur in a subset of individuals, with reports of autoimmune brain inflammation and demyelinating conditions resembling multiple sclerosis. Lung involvement may manifest as interstitial lung disease or lymphocytic infiltration. The combination of autoimmunity and immune deficiency creates a paradoxical clinical picture where the immune system is simultaneously overactive against self-tissues and underactive against pathogens. Symptoms often fluctuate over time, with periods of relative stability punctuated by acute flares requiring medical intervention.
Video: Genetics 101
Affected organs
The immune system itself bears the primary defect, with T-lymphocytes exhibiting excessive activation and proliferation. This leads to lymphocytic infiltration of multiple organs, including the gastrointestinal tract, lungs, liver, and central nervous system. The spleen and lymph nodes typically enlarge due to accumulation of activated immune cells.
Autoimmune attack can damage virtually any organ system. The endocrine system is frequently affected, particularly the thyroid and pancreas. The haematological system commonly shows cytopenias as antibodies target blood cells. Skin, joints, and the nervous system may also experience immune-mediated inflammation, though the specific pattern of organ involvement varies considerably between affected individuals.
Risks & severity
Disease severity spans a broad spectrum. Some individuals experience life-threatening complications including severe autoimmune cytopenias, progressive lung disease, or neurological deterioration, whilst others have relatively mild symptoms manageable with standard immunosuppression. Early-onset disease, particularly when presenting before age 10, may indicate more severe phenotype, though exceptions occur.
The risk of developing malignancy, particularly lymphoma, appears elevated compared to the general population, though precise figures remain uncertain given the condition's rarity. Progressive organ damage from chronic inflammation represents a significant long-term concern, particularly affecting the lungs, liver, and nervous system. Infectious complications during immunosuppressive treatment contribute additional morbidity. Life expectancy varies with disease severity and access to appropriate immune modulation, with some individuals experiencing near-normal lifespan whilst others face serious complications requiring intensive medical management.
Genetic causes
CTLA4 encodes a receptor expressed on T-lymphocytes that delivers inhibitory signals preventing excessive immune activation. The normal CTLA-4 protein competes with CD28, a stimulatory receptor, for binding to molecules on antigen-presenting cells. When CTLA-4 engages these molecules, it dampens T-cell responses and promotes immune tolerance. Research suggests this mechanism is essential for maintaining self-tolerance and preventing autoimmunity.
Pathogenic variants causing CTLA-4 haploinsufficiency typically result in reduced protein levels rather than complete absence. With only one functional CTLA4 copy, cells produce insufficient CTLA-4 to adequately restrain immune activation. Some variants affect protein trafficking to the cell surface, whilst others reduce messenger RNA stability or protein production. The consequence is a threshold effect - when CTLA-4 levels fall below approximately 50% of normal, regulatory function becomes inadequate to prevent immune dysregulation.
- CTLA4 cytotoxic T-lymphocyte associated protein 4
Inheritance pattern
CTLA-4 haploinsufficiency follows an autosomal dominant pattern, meaning a pathogenic variant in one copy of CTLA4 is sufficient to cause disease. Each child of an affected parent has a 50% chance of inheriting the variant. However, the condition shows incomplete penetrance and variable expressivity - not everyone carrying a pathogenic variant develops symptoms, and those who do may experience very different clinical courses.
This variability complicates genetic counselling, as identifying a familial variant does not guarantee disease development or predict severity. Some family members carrying the same variant remain asymptomatic whilst others require significant medical intervention. Additional genetic modifiers and environmental factors likely influence whether and how the condition manifests. Spontaneous (de novo) variants account for some cases where neither parent carries the pathogenic change.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis typically begins with clinical suspicion based on the combination of autoimmunity, immune deficiency, and lymphoproliferation. Immunological investigations often reveal reduced CTLA-4 expression on T-lymphocytes, abnormal T-cell populations, and elevated immunoglobulin levels. Genetic testing confirms the diagnosis by identifying a pathogenic CTLA4 variant.
Within the NHS Genomic Medicine Service, testing for CTLA-4 haploinsufficiency may be accessed through the Primary immunodeficiency disorders R134 test directory or related immune dysregulation panels. Referral typically comes from immunology or clinical genetics services following assessment of the clinical and immunological phenotype. Genetic counsellors provide pre- and post-test information, discussing inheritance implications and supporting family communication.
Management & lifestyle
Treatment focuses on immune modulation to reduce autoimmunity whilst managing infection risk. Many individuals require immunosuppressive medications such as corticosteroids, azathioprine, or mycophenolate to control autoimmune manifestations. Immunoglobulin replacement therapy may benefit those with significant antibody deficiency and recurrent infections.
Abatacept, a fusion protein that mimics CTLA-4 function, has shown promise in some individuals by providing the missing regulatory signal. This targeted approach addresses the underlying mechanism rather than broadly suppressing immunity. Regular monitoring includes blood counts, immunoglobulin levels, and organ-specific surveillance depending on which systems are affected. Prophylactic antibiotics may be considered for those with severe immune deficiency. Management requires coordination between immunology, clinical genetics, and relevant organ specialists, with treatment individualised based on each person's specific manifestations and disease severity. Genetic counselling supports family planning decisions and facilitates predictive testing discussions for at-risk relatives.
UK care pathway
Individuals with suspected CTLA-4 haploinsufficiency typically enter NHS care through immunology or paediatric services following investigation of recurrent infections or autoimmune complications. Genetic testing is accessed via the NHS Genomic Medicine Service through appropriate test directories, most commonly R134 for primary immunodeficiencies. Regional genetic laboratories analyse CTLA4 alongside related genes depending on the clinical presentation.
Clinical genetics services provide diagnostic confirmation, inheritance counselling, and cascade testing for family members. Genetic counsellors offer essential support in understanding test results, discussing reproductive implications, and facilitating communication with relatives who may wish to pursue predictive testing. Ongoing clinical management typically involves immunology centres with expertise in primary immunodeficiency and immune dysregulation, often within specialist centres offering multidisciplinary input from haematology, gastroenterology, and other relevant specialties.
Frequently asked questions
Will my children definitely develop symptoms if they inherit the CTLA4 variant?
Not necessarily. CTLA-4 haploinsufficiency shows incomplete penetrance, meaning some people carrying a pathogenic variant remain healthy or develop only mild symptoms. However, predicting individual outcomes is difficult, and genetic counsellors can discuss the uncertainties involved in family planning decisions.
Can CTLA-4 haploinsufficiency be cured?
Currently no cure exists, though haematopoietic stem cell transplantation has been considered in severe cases. Most individuals require ongoing immune modulation to control symptoms. Targeted therapies like abatacept may offer better disease control by addressing the underlying regulatory defect rather than broadly suppressing immunity.
How often will I need medical monitoring?
Monitoring frequency depends on disease severity and which organs are affected. Many people require blood tests every few months to check blood counts and immunoglobulin levels, with additional organ-specific surveillance as needed. Your immunology team will create an individualised monitoring schedule based on your specific manifestations.
Should other family members be tested?
Once a pathogenic CTLA4 variant is identified, cascade testing can be offered to at-risk relatives. This allows early identification of variant carriers who might benefit from monitoring or early intervention if symptoms develop. Genetic counsellors can help families navigate these decisions and coordinate appropriate testing through clinical genetics services.
References
- Schubert D, Bode C, Kenefeck R. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nature medicine. 2014. PMID: 25329329
- Turnbull C, Bones J, Stanley M. DECTIN-1: A modifier protein in CTLA-4 haploinsufficiency. Science advances. 2023. PMID: 38055819
- Jamee M, Hosseinzadeh S, Sharifinejad N. Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review. Clinical and experimental immunology. 2021. PMID: 33788257
- Negrini S, Nicola S, Badiu I. The CTLA-4 Pathway in Human Disease: Molecular Mechanisms and Therapeutic Targeting. Genes. 2026. PMID: 42195030
- Krone KA, Winant AJ, Vargas SO. Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency. Pediatric pulmonology. 2021. PMID: 33710794
- Brodsky NN, Kennedy A, Glaser D. Immune dysregulation from a novel CTLA-4 haploinsufficiency variant. Journal of human immunity. 2026. PMID: 41608053
- Kohatsu K, Suzuki T, Takimoto M. Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report. BMC nephrology. 2022. PMID: 36384506
- Kanegane H, Hoshino A, Okano T. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergology international : official journal of the Japanese Society of Allergology. 2018. PMID: 28684198